SCHEMBL339928

SCHEMBL339928

Brc1ccc2cccc(Br)c2n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.63
AR P10275 1/20 0.41
HSP90AA1 P07900 3/20 0.38
NPC1 O15118 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
RAB9A P51151 2/20 0.38
NOS1 P29475 1/20 0.38
LMNA P02545 3/20 0.37
KDM4E B2RXH2 3/20 0.37
CYP3A4 P08684 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HTT P42858 2/20 0.37
MAPT P10636 2/20 0.37
TSHR P16473 2/20 0.37
GMNN O75496 1/20 0.37
TP53 P04637 1/20 0.37
MMP2 P08253 1/20 0.37
CYP2D6 P10635 1/20 0.37
MMP9 P14780 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30657716 1.00 BACE1 (0.63) BACE1ARHSP90AA1NPC1MEN1
SCHEMBL57528 0.79 CCR1 (0.43) BACE1HSP90AA1RAB9ALMNAKDM4E
SCHEMBL5763166 0.77 BACE1 (0.59) BACE1ARHSP90AA1NPC1MEN1
SCHEMBL340255 0.77 METAP2 (0.59) BACE1ARMEN1KMT2ARAB9A
SCHEMBL1030675 0.77 BACE1 (0.64) BACE1ARHSP90AA1NPC1MEN1
SCHEMBL15228915 0.77 BACE1 (1.00) BACE1PLAUNCF1
SCHEMBL16535454 0.77 BACE1 (0.59) BACE1ARHSP90AA1NPC1MEN1
SCHEMBL4134465 0.77 BACE1 (0.59) BACE1ARHSP90AA1NPC1MEN1
SCHEMBL22119746 0.77 BACE1 (0.48) BACE1HSP90AA1NPC1MEN1KMT2A
SCHEMBL3850693 0.77 XPO1 (0.41) BACE1ARHSP90AA1NPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110041905-B Fluorescent and phosphorescent dual luminescent material with switching effect and preparation method thereof 华中科技大学 2020-05-19 CN claimed
EP-4701783-A1 PHOSPHINE-IMINO-QUINOLINE AND RELATED LIGANDS FOR USE IN ETHYLENE OLIGOMERIZATION PROCESSES Chevron Phillips Chemical Company LP (US) 2026-03-04 EP disclosed
EP-4701782-A1 CATALYST SYSTEM AND ETHYLENE OLIGOMERIZATION PROCESS FOR THE PREPARATION OF LINEAR ALPHA OLEFINS Chevron Phillips Chemical Company LP (US) 2026-03-04 EP disclosed
US-20240400473-A1 CATALYST SYSTEM AND ETHYLENE OLIGOMERIZATION PROCESS FOR THE PREPARATION OF LINEAR ALPHA OLEFINS CHEVRON PHILLIPS CHEMICAL COMPANY LP 2024-12-05 US disclosed
US-20240360052-A1 PHOSPHINE-IMINO-QUINOLINE AND RELATED LIGANDS FOR USE IN ETHYLENE OLIGOMERIZATION PROCESSES CHEVRON PHILLIPS CHEMICAL COMPANY LP 2024-10-31 US disclosed
WO-2024226497-A1 CATALYST SYSTEM AND ETHYLENE OLIGOMERIZATION PROCESS FOR THE PREPARATION OF LINEAR ALPHA OLEFINS CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2024-10-31 WO disclosed
WO-2024226492-A1 PHOSPHINE-IMINO-QUINOLINE AND RELATED LIGANDS FOR USE IN ETHYLENE OLIGOMERIZATION PROCESSES CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2024-10-31 WO disclosed
CN-118271332-A Organic compound and display panel 武汉华星光电半导体显示技术有限公司 2024-07-02 CN disclosed
CN-117024419-A Chiral 2-oxazoline-8-imine quinoline compound and metal complex thereof, preparation method and application 浙江大学 2023-11-10 CN disclosed
US-11198745-B2 Poly(alpha-olefin)s and methods thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2021-12-14 US disclosed
WO-2011011040-A1 CATALYSTS BASED ON 2-(2-ARYLOXY) QUINOLINE OR 2-(2-ARYLOXY) DIHYDROQUNIOLINE LIGANDS EQUISTAR CHEMICALS, LP (US) 2011-01-27 WO disclosed
US-7858718-B1 Catalysts based on 2-aryl-8-anilinoquinoline ligands EQUISTAR CHEMICALS, LP (US) 2010-12-28 US disclosed
US-7858718-B1 Catalysts based on 2-aryl-8-anilinoquinoline ligands EQUISTAR CHEMICALS, LP (US) 2010-12-28 US disclosed
US-20100144751-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-06-10 US disclosed
WO-2010022081-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-02-25 WO disclosed
US-20100029633-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-02-04 US disclosed
EP-2139888-A2 IMIDAZOÝ1,2-A¨PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2010-01-06 EP disclosed
EP-2137184-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2009-12-30 EP disclosed
WO-2008124323-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2008-10-16 WO disclosed
WO-2008121687-A2 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029633-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS PIM1, PIM3, PIM2 BACE1 4126/4885AR 1091/4885HSP90AA1 3229/4885
US-20240360052-A1 PHOSPHINE-IMINO-QUINOLINE AND RELATED LIGANDS FOR USE IN ETHYLENE OLIGOMERIZATION PROCESSES PHOSPHO1, PEBP1, PPIP5K2 BACE1 2471/4885AR 4752/4885HSP90AA1 4697/4885
US-20100144751-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS PIM1, PIM3, PIM2 BACE1 4467/4885AR 2295/4885HSP90AA1 2155/4885
US-11198745-B2 Poly(alpha-olefin)s and methods thereof PUF60, DEGS1, POLL BACE1 777/4885AR 3349/4885HSP90AA1 1209/4885
US-20240400473-A1 CATALYST SYSTEM AND ETHYLENE OLIGOMERIZATION PROCESS FOR THE PREPARATION OF LINEAR ALPHA OLEFINS AP1M1, AP2M1, OXER1 BACE1 1039/4885AR 2461/4885HSP90AA1 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.